APC and colorectal neoplasm: Our intermediate aim was to identify sensitization effects that operated in a variety of APC mutant colorectal tumour cell lines; by intersecting the data from both COLO320DM and SW480 screens, we identified two drugs that caused MSC2504877 sensitivity in both: the mutlikinase inhibitor, dasatinib, identified in earlier work19, and the CDK4/6 kinase inhibitor palbociclib (PF-332991).